CD19 and non-Hodgkin lymphoma: In a phase I/II trial of tandem CD19/CD20 CAR-T therapy, the best ORR in 87 patients with R/R non-Hodgkin lymphoma (NHL) was 78% (95% CI, 68 to 86) and the median PFS was 27.6 months (38).